New approval paths are needed, says Woodcock

Share this article:

FDA director of drugs Janet Woodcock says she is so optimistic that biomedical science and the war on cancer will produce “startlingly better” therapies that the research community should develop new approval paths.

At the Conference on Clinical Cancer Research sponsored by the Engelberg Center on Health Care Reform and Friends of Cancer Research in November, she said that, for example, with many metastatic solid tumors, if many complete responses are seen in an initial Phase 1 trial, “we should all stop and think about what to do next.”

Woodcock was on a panel that wrote the issue brief  “Development Paths for New Drugs with Large Treatment Effects Seen Early.” It noted: “Randomized Phase 2 and Phase 3 trials provide the most reliable evidence,” but  they “can be extremely time consuming, expensive and difficult to perform.”

That brief proposed an alternative pathway to full approval consisting of a small randomized Phase 2b trial, with about 120 to 150 patients. The purpose, said the brief, “is to demonstrate a large treatment effect in a small number of patients, while maintaining the same statistical significance currently used in trials that seek small benefits.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Antidote: On Cystic Fibrosis treatments

Antidote: On Cystic Fibrosis treatments

Recent treatments in CF, including the inhaled antibiotic Tobramycin, have increased lifespan well into adulthood.

The $3 generic and the $1,000 pill: pharma outsiders just don't get it

The $3 generic and the $1,000 pill: pharma ...

What do you call the people who treat medical breakthroughs as if they were bank heists? Malicious? Uninformed? Not with it?

Leadership Exchange Uncut : The Agency-Client Relationship

Leadership Exchange Uncut : The Agency-Client Relationship

Click the above link to access MM&M's first Leadership Exchange Uncut e-book, "The Agency-Client Relationship"